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Abstract
A series of potent electrophilic affinity labels (IC50 = 0.1-5 nM) containing either a bromoacetamide
or isothiocyanate based on the mu opioid receptor (MOR) selective peptide dermorphin were
prepared. All four analogs exhibited wash resistant inhibition of [3H]DAMGO binding at
subnanomolar to nanomolar concentrations, suggesting that these analogs bind covalently to MOR.
To our knowledge these peptides are the highest affinity peptide-based affinity labels for MOR
reported to date.
Narcotic analgesics produce pain relief generally through activation of mu opioid receptors
(MOR),# but the use of these analgesics is limited by their side effects, namely respiratory
depression, tolerance, constipation and physical dependence.1 Therefore there is an ongoing
need to develop novel analgesics with fewer side effects. Understanding receptor-ligand
interactions at the molecular level can facilitate the design of novel opioid ligands. Since the
cloning of the three major opioid receptors, MOR, delta opioid receptors (DOR) and kappa
opioid receptors (KOR), in the 1990s and determination of their sequences,2, 3 there have been
considerable advancements in understanding opioid receptor-ligand interactions. These studies
have utilized chimeric receptors (such as MOR/KOR chimeras, etc.) and site-directed
mutagenesis.4 Although these approaches have provided considerable information regarding
receptor-ligand interactions, interpreting the results can be complicated by changes in the
secondary or tertiary structures of the proteins.4 Also while these approaches provide
information about which residues in the receptor may interact with the ligand, they often do
not provide information about what portions of the ligand are involved in these interactions.
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Since pain relief is mediated mainly through MOR, it is important to understand the interactions
between MOR ligands and the receptor. The endogenous ligands of opioid receptors are
peptides, and studies of chimeric opioid receptors and site-directed mutagenesis suggest that
peptide ligands may interact differently with opioid receptors than non-peptide ligands.4
Therefore information about peptide ligands interactions with opioid receptors is
complimentary to that obtained for nonpeptide ligands.
Affinity labels, which are ligands that interact with their target in a non-equilibrium manner,
5 can provide detailed information about specific receptor-ligand interactions,6, 7 and the
information obtained from affinity labels can compliment results obtained from molecular
biology and computational methods. The interaction of affinity labels with the receptor occurs
in a two-step manner.5 In the first step, the ligand binds reversibly to its receptor. In the second
step, which can further increase the selectivity of the ligand for its receptor, the ligand binds
irreversibly, provided an appropriate nucleophile in the receptor is in close proximity to the
reactive group in the ligand. Affinity labels can be either photoaffinity or electrophilic affinity
labels. The electrophilic affinity label naltrexamine derivative β-funaltrexamine (β-FNA), a
well studied affinity label for MOR, was the first affinity label (and one of only two affinity
labels8) for opioid receptors whose covalent attachment point (Lys233 in MOR) has been
successfully determined.7
Although a number of non-peptide affinity labels for opioid receptors have been reported in
the literature,1, 5 until recently peptide-based affinity labels have been mostly limited to
photoaffinity labels.5 A disadvantage of using azido photoaffinity labels is that short
wavelength UV irradiation generally used to generate the reactive species can inactivate opioid
receptors.9 Alkylation of the receptor by electrophilic affinity labels, on the other hand, depends
on the selectivity and chemical reactivity of the electrophile, and thus is not subject to the
receptor inactivation that can occur with photoaffinity labels. Examples of peptide-based
electrophilic affinity labels, selective for DOR, that have been reported include [D-
Ala2,Cys6]enkephalin (DALCE),10 the chloromethyl ketone of [DAla2,Leu5]enkephalin,11
and isothiocyanate and bromoacetamide-containing derivatives of TIPP (Tyr-Tic-Phe-Phe)
and other DOR opioid peptides discovered in our laboratory (see ref. 12). There have been very
few reports of electrophilic peptide-based affinity labels selective for MOR. The chloromethyl
ketone of Tyr-D-Ala-Gly-NMePhe (IC50 = 1-5 μM for concentration-dependent irreversible
inhibition of [3H]naloxone binding)13 and Tyr-D-Ala-Gly-Phe-Leu(CH2SNpys) (Npys = 3-
nitro-2-pyridinesulphenyl, IC50 = 19 nM for concentration-dependent inhibition of [3H]
DAMGO binding)14 are the only examples of peptide-based electrophilic affinity labels for
MOR reported in the literature. Previous attempts in our group to prepare affinity labels for
MOR by incorporating an electrophilic functionality such as bromoacetamide or isothiocyanate
at the para position of either Phe3 or Phe4 in endomorphin-2 (Tyr-Pro-Phe-PheNH2) were
unsuccessful because the modified analogs exhibited large (40- to 80-fold) decreases in MOR
binding affinity compared to endomorphin-2.15
Dermorphin (Fig. 1), an endogenous peptide from South American frog skin,16 was selected
as the parent ligand for further modification in the present study. Dermorphin is a highly
selective ligand for MOR that has 100-fold higher affinity than morphine for MOR.16 The
characteristic feature of frog skin peptides are their N-terminal Tyr-D-aa-Phe sequence, which
constitutes the ‘message’ domain17 of these peptides. The D-configuration at position 2 of
dermorphin is critical for MOR binding and opioid activity.16 Previously, we modified the para
position of Phe3 or a Phe in position 5 of dermorphin and [Lys7]dermorphin to introduce an
electrophilic functionality, i.e. a bromoacetamide or an isothiocyanate group.18 Modification
in the ‘message’ domain (Phe3) resulted in >1000-fold decrease in MOR affinity. While
modification of a Phe in position 5 in the ‘address’ domain of dermorphin and [Lys7]
dermorphin was well tolerated and the peptides retain nanomolar affinity for MOR, none of
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these modified analogs exhibited wash-resistant inhibition of binding (WRIB) to MOR, and
therefore are not affinity labels for these receptors.18
Therefore in the present study we chose an alternative location in the ‘message’ sequence,
position 2, to incorporate a reactive functionality. Larger D-amino acids are tolerated at this
position in peptides by MOR,16 suggesting that introduction of a functionality such as an
affinity label into the side chain of this residue would not interfere with the binding of these
ligands to the receptor. In the present study, D-Ala at position 2 was replaced by either D-Orn
or D-Lys. The free amine on the side chain of these amino acids was used as a suitable handle
to incorporate the electrophilic bromoacetamide or isothiocyanate functionalities (Fig. 1). This
strategy also permits varying the length of the amino acid side chain to optimize binding of the
affinity label to its receptor. For these series of analogs, [D-Orn(COCH3)2]- and [D-Lys
(COCH3)2]dermorphin served as reversible control peptides for the respective series of
compounds in the pharmacological assays.
Solid phase synthesis of the peptides was carried out on the PAL-PEG-PS (Peptide Amide
Linker-poly(ethylene glycol)-polystyrene) resin using Fmoc (9-fluorenylmethoxycarbonyl)-
protected amino acids, except for the N-terminal Tyr residue which was protected with the Boc
(t-butyloxycarbonyl) group. The peptides were synthesized according to methods previously
developed in our laboratory12, 19 (see Supporting Information). The side chains of Tyr and Ser
were protected with the tBu group, and the side chain of D-Orn or D-Lys was protected with
the Aloc (allyloxycarbonyl) group. Once the protected full-length peptide was assembled, the
Aloc group was selectively deprotected using tetrakis (triphenylphosphine) palladium(0) and
phenyl silane, 19, 20 and the resins were then divided into three equal parts. The free amine in
each part was treated with either bromoacetic acid, thiocarbonyldiimidazole or acetic anhydride
to obtain the bromoacetamide, isothiocyanate or acetylated derivatives, respectively (see
Supporting Information for details). The completion of the reactions was confirmed by the
qualitative ninhydrin test. The final peptides were cleaved from the resins using 95%
trifluoroacetic acid and 5% water for 2 h, and the peptides were purified using reversed phase
preparative HPLC. The molecular weights of the peptides were confirmed by electrospray
ionization mass spectrometry analysis, and the purity of the final peptides was verified using
two HPLC systems (see Supporting Information).
The binding affinities of these peptides for opioid receptors were initially measured in
radioligand binding assays using Chinese hamster ovary cells stably expressing MOR and
DOR, with [3H]DAMGO ([D-Ala2,MeNPhe4,glyol]enkephalin) and [3H]DPDPE (cyclo[D-
Pen2,D-Pen5]enkephalin) as the radioligands, respectively, under standard conditions (see
Supporting Information21). All of the compounds retain subnanomolar to nanomolar affinity
for MOR (Table 1). Of the analogs prepared, 1, 2 and 4 exhibit the highest affinities for MOR
(subnanomolar IC50 values), affinities that are markedly higher compared to the previously
prepared Phe3 substituted analogs (IC50 = 40-6050 nM).18 In addition, these three potential
affinity labels exhibit equal or higher affinity (7 and 2 times higher for analogs 2 and 4,
respectively) than the parent peptide dermorphin.
The isothiocyanate-containing affinity labels in the two series (D-Orn and D-Lys) exhibit
similar binding affinities for MOR, while the affinity of the bromoacetamide derivative in the
D-Orn series 2 is 48 times higher than the corresponding D-Lys derivative 5. Similarly, the
acetylated control compound in the D-Orn series, 3, exhibits significantly higher affinity than
the corresponding control compound 6 in the D-Lys series. Clearly, the different lengths of the
side chains in D-Lys and D-Orn as well as the identity of the attached functionality play
important roles in determining the affinities of the dermorphin analogs for MOR. In the case
of the bromoacetamide analogs and the control compounds, the extra methylene group in the
side chain of D-Lys is probably causing unfavorable steric interactions, resulting in decreases
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in MOR affinity. In contrast, the isothiocyanate analogs in the two series do not differ
substantially in MOR binding affinity. The smaller size of the isothiocyanate group compared
to the acetamide and bromoacetamide probably counterbalances the size increases due to the
extra methylene group in the side chain of D-Lys that resulted in unfavorable interactions with
MOR.
Comparing the affinities of these peptides for DOR, the isothiocyanate derivative in the D-Orn
series, 1, exhibits the highest affinity for DOR, four times higher than the affinity of the
corresponding analog 3 in the D-Lys series. The acetylated control compound and
bromoacetamide analogs in both series (compounds 2, 3, 5 and 6) show lower affinity for DOR
compared to dermorphin; no other major differences in DOR affinities were observed between
the two series.
Except for the isothiocyanate derivatives, the D-Orn series of compounds are more selective
for MOR over DOR than the corresponding D-Lys compounds. The affinity label derivative
with the highest selectivity is [D-Orn(COCH2Br)2]dermorphin, 2, which exhibits >3000-fold
difference in the IC50 values for MOR vs. DOR, and is 49-fold more selective than the
reversible control 3 and 11-fold more selective than the parent peptide (Table 1). In contrast,
[D-Lys(COCH2Br)2]-dermorphin exhibits 4-fold lower selectivity for MOR compared to
dermorphin due to the large decrease in MOR affinity. For the isothiocyanate derivatives,
however, the trend in selectivity is reversed. The D-Orn(=C=S)2 derivative 1 is 9-fold less
selective for MOR than dermorphin and also [D-Lys(=C=S)2]-dermorphin, 4. The selectivities
were calculated using IC50 values, which vary as a function of the radioligand concentration
used; therefore comparison of the selectivities for these peptides to those reported in other
studies should be made with caution.
Since all four potential affinity labels show subnanomolar to nanomolar affinity for MOR, they
were examined to determine whether they may bind to MOR covalently. WRIB of [3H]
DAMGO by these four analogs, 1, 2, 4 and 5, at concentrations approximately equal to their
IC50 values, was determined according to the procedure described previously (see Supporting
Information).22 The acetylated derivatives 3 and 6 were included as reversible controls to verify
that the washing procedure completely removed noncovalently bound compound; the washing
procedure removed >80% of both reversible control peptides. In the D-Orn series, [D-Orn
(=C=S)2]dermorphin (1) at a subnanomolar concentration caused 40 ± 8% inhibition of [3H]
DAMGO binding compared to control (P<0.001) even after extensive washing of the
membranes (Fig. 2), suggesting that this peptide is binding covalently to a nearby nucleophile
in the binding site of MOR. [D-Orn(COCH2Br)2]dermorphin (2), which shows the highest
MOR affinity of all the compounds tested, did not exhibit WRIB to MOR when initially tested
at a concentration equal to its IC50 (0.11 nM, Fig. 2), but was effectively removed by the
washing procedure. However, when the WRIB experiments were repeated at higher
concentrations this analog (2) did show concentration-dependent WRIB that was statistically
significant compared to the control (P<0.001) (Fig. 3).
In the D-Lys series, both the bromoacetamide and isothiocyanate derivatives exhibit
statistically significant (P<0.001) inhibition of [3H]DAMGO binding after extensive washing
when evaluated at their IC50 values (Fig. 2). The inhibition of [3H]DAMGO binding by these
ligands 4 and 5 were 31 ± 2% and 32 ± 1%, respectively (Fig. 2). Moreover, [D-Lys(=C=S)2]
dermorphin (4) exhibits concentration-dependent inhibition of [3H]DAMGO binding (Fig. 4)
when WRIB experiments of 4 were performed at higher concentrations of 4 and 40 nM
(P<0.001).
Comparison of the binding affinities reported for previous MOR selective affinity labels and
the analogs discovered in the present study indicate that the dermorphin-based affinity labels
Sinha et al. Page 4













have substantially higher MOR affinity. Previously Tyr-D-Ala-Gly-Phe-Leu(CH2SNpys) was
reported to be the highest affinity peptide-based electrophilic affinity label for MOR (IC50 =
19 nM for irreversible binding); however it lacks selectivity and also shows nanomolar affinity
for DOR (IC50 = 12 nM).14 Importantly, three of the four affinity label derivatives reported
here, [D-Orn(=C=S)2]- (1), [D-Orn(-COCH2Br)2]- (2) and [D-Lys(=C=S)2]dermorphin (5),
appear to have higher affinity (approximately 3- to 20-fold) than the well-studied nonpeptide
MOR affinity label β-FNA (IC50 = 2.2 nM).6, 23
In conclusion, we have successfully identified a series of dermorphin-based affinity label
analogs that show exceptionally high affinity (IC50 = 0.1-5 nM) for MOR. These analogs were
designed by modifying position 2 of dermorphin, which is a new strategy for designing peptide-
based affinity label derivatives of opioid peptides that has not been previously reported. This
resulted in a substantial improvement in binding affinity (between 10- to 100-fold) compared
to the previous dermorphin-based analogs synthesized in our laboratory in which the para
position of Phe3 or a Phe in position 5 of dermorphin or [Lys7]dermorphin were modified.18
All four potential affinity labels in the present study show subnanomolar to nanomolar affinity
for MOR in standard binding assays, indicating favorable interactions of the side chains in [D-
Orn(X)2]dermorphin and [D-Lys(X)2]dermorphin (X= -COCH2Br or =C=S) with the binding
pocket of MOR. [D-Orn(COCH2Br)2]dermorphin (2) shows exceptional selectivity for MOR
over DOR, and [D-Lys(C=S)2]dermorphin (4) exhibits selectivity comparable to the parent
peptide dermorphin. All four potential affinity labels also exhibit WRIB to MOR, suggesting
that these compounds are electrophilic affinity labels that bind covalently to MOR. Three of
the four affinity label peptides exhibit WRIB to MOR at < 1 nM. Thus we have identified
peptide-based electrophillic affinity labels with exceptionally high affinity for MOR. These
novel dermorphin analogs will be valuable tools to study MOR and the interactions of the
peptides with this receptor. The next step will be to use these peptide-based electrophilic
affinity labels to characterize MOR. These studies are currently underway in our laboratory.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Affinity label derivatives for MOR and the corresponding reversible control peptides based on
the parent peptide dermorphin
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(A) WRIB by [D-Orn2]dermorphin and (B) [D-Lys2]dermorphin derivatives. The
concentrations of the peptides in the incubations, which are approximately equal to their
IC50 values, are indicated in parenthesis. *p<0.05, *** p<0.001 compared to control
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Concentration-dependent WRIB by [D-Orn(-COCH2Br)2]dermorphin (2). *** p<0.001
compared to control
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Concentration-dependent WRIB by [D-Lys(C=S)2]dermorphin (4). ***p<0.001 compared to
control
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Table 1
Binding affinities of dermorphin derivatives for MOR and DOR a
Dermorphin
Analogs








1 [D-Orn(=C=S)2] 0.81 ± 0.29 23.8 ±2.1 0.89 29
2 [D-Orn(COCH2Br)
2] 0.11 ± 0.02 342 ± 20 6.54 3110
3 [D-Orn(COCH3)
2] 4.25 ± 0.35 272 ± 23 0.17 64
4 [D-Lys(=C=S)2] 0.38 ± 0.08 97.1 ±4.9 1.89 255
5 [D-Lys(COCH2Br)
2] 5.23 ± 2.31 382 ± 22 0.14 73
6 [D-Lys(COCH3)
2] 29.8 ± 7.6 436 ± 34 0.02 15
Dermorphinc 0.72 ± 0.07 197 ± 28 1.0 274
a
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